Literature DB >> 3517163

Suppressive effects of insulin and insulin-like growth factor-1 (IGF1) on immune responses.

P Hunt, D D Eardley.   

Abstract

This paper describes conditions wherein the serum peptides insulin and IGF1, which are typically associated with growth-promoting functions, can suppress in vitro immune responses. IL 2-induced proliferation of lymphocytes as well as in vitro antibody-producing cultures are suppressed by physiologic concentrations of IGF1 or by superphysiologic concentrations of insulin. Suppression of IL 2-induced proliferation is not overcome by increasing the IL 2 concentration and is mediated only during the first 24 to 48 hr of the 110-hr incubation period required to measure the proliferative response to IL 2. By analogy to other biologic systems, these effects of insulin and of IGF1 are probably mediated by occupancy of the IGF1-receptor, which is cross-occupied by insulin at superphysiologic concentrations. These data support the possibility of a novel function for these endocrine and endocrine-like peptides and also expands their range of biologic activities to within the immune system.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3517163

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

1.  A model to explain specific cellular communications and cellular harmony:- a hypothesis of coupled cells and interactive coupling molecules.

Authors:  Cyril J Craven
Journal:  Theor Biol Med Model       Date:  2014-09-14       Impact factor: 2.432

Review 2.  Multiple immunological abnormalities in patients with type 1 (insulin-dependent) diabetes mellitus.

Authors:  D W Drell; A L Notkins
Journal:  Diabetologia       Date:  1987-03       Impact factor: 10.122

Review 3.  Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases?

Authors:  Terry J Smith
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

Review 4.  Prophylactic insulin. Is it 'safe'?

Authors:  K Buschard; T Bock; C Pedersen; I Hageman; K Josefsen
Journal:  Drug Saf       Date:  1993-11       Impact factor: 5.606

5.  Structural and functional characterization of the human T lymphocyte receptor for insulin-like growth factor I in vitro.

Authors:  V F Tapson; M Boni-Schnetzler; P F Pilch; D M Center; J S Berman
Journal:  J Clin Invest       Date:  1988-09       Impact factor: 14.808

6.  Immunological effects of insulin-like growth factor-I--enhancement of immunoglobulin synthesis.

Authors:  K Robbins; S McCabe; T Scheiner; J Strasser; R Clark; P Jardieu
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

7.  Insulin-dependent diabetes and serious trauma.

Authors:  D Z Liou; M B Singer; G Barmparas; M Y Harada; J Mirocha; M Bukur; A Salim; E J Ley
Journal:  Eur J Trauma Emerg Surg       Date:  2015-08-08       Impact factor: 3.693

8.  Evidence for suppression of immune function by insulin-like growth factor-1 in dwarf rats in vivo.

Authors:  A Schurmann; G S Spencer; C J Berry; E Decuypere; B Goddeeris
Journal:  Experientia       Date:  1996-01-16

9.  Insulin prevents adoptive cell transfer of diabetes in the autoimmune non-obese diabetic mouse.

Authors:  C H Thivolet; E Goillot; P Bedossa; A Durand; M Bonnard; J Orgiazzi
Journal:  Diabetologia       Date:  1991-05       Impact factor: 10.122

10.  Effects of Sertoli cell transplants in a 3-nitropropionic acid model of early Huntington's disease: a preliminary study.

Authors:  Alba I Rodriguez; Alison E Willing; Samuel Saporta; Don F Cameron; Paul R Sanberg
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.